The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
- PMID: 21068142
- DOI: 10.1093/ndt/gfq665
The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
Abstract
Background: Little is known about the worldwide variation in incidence of primary glomerulonephritis (GN). The objective of this review was to critically appraise studies of incidence published in 1980-2010 so that an overall view of trends of these diseases can be found. This would provide important information for determining changes in rates and understanding variations between countries.
Methods: All relevant papers found through searches of Medline, Embase and ScienceDirect were critically appraised and an assessment was made of the reliability of the reported incidence data.
Results: This review includes 40 studies of incidence of primary GN from Europe, North and South America, Canada, Australasia and the Middle East. Rates for the individual types of disease were found to be in adults, 0.2/100,000/year for membrano-proliferative GN, 0.2/100,000/year for mesangio-proliferative GN, 0.6/100,000/year for minimal change disease, 0.8/100,000/year for focal segmental glomerulosclerosis, 1.2/100,000/year for membranous nephropathy and 2.5/100,000/year for IgA nephropathy. Rates were lower in children at around 0.1/100,000/year with the exception of minimal change disease where incidence was reported to be 2.0/100,000/year in Caucasian children with higher rates in Arabian children (9.2/100,000/year) and Asian children (6.2-15.6/100,000/year).
Conclusions: This study found that incidence rates of primary GN vary between 0.2/100,000/year and 2.5/100,000/year. The incidence of IgA nephropathy is at least 2.5/100,000/year in adults; this disease can exist subclinically and is therefore only detected by chance in some patients. In addition, referral policies for diagnostic biopsy vary between countries. This will affect the incidence rates found.
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
-
Interventions targeted at women to encourage the uptake of cervical screening.Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3. Cochrane Database Syst Rev. 2021. PMID: 34694000 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
Cited by
-
Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.Front Pharmacol. 2024 Aug 21;15:1394997. doi: 10.3389/fphar.2024.1394997. eCollection 2024. Front Pharmacol. 2024. PMID: 39234105 Free PMC article. Review.
-
A novel peptide ligand-coated nano-siRNA-lipoplex technology for kidney targeted gene therapy.Am J Transl Res. 2022 Oct 15;14(10):7362-7377. eCollection 2022. Am J Transl Res. 2022. PMID: 36398217 Free PMC article.
-
Identification of hub genes and their correlation with immune infiltrating cells in membranous nephropathy: an integrated bioinformatics analysis.Eur J Med Res. 2023 Nov 16;28(1):525. doi: 10.1186/s40001-023-01311-3. Eur J Med Res. 2023. PMID: 37974210 Free PMC article.
-
Urinary exosomal miRNA signature of IgA nephropathy: a case-control study.Sci Rep. 2023 Dec 4;13(1):21400. doi: 10.1038/s41598-023-47751-z. Sci Rep. 2023. PMID: 38049447 Free PMC article.
-
Targeting complement in IgA nephropathy.Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii28-ii39. doi: 10.1093/ckj/sfad198. eCollection 2023 Dec. Clin Kidney J. 2023. PMID: 38053977 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous